Multiple Sclerosis, Relapsing-Remitting: all 615 studies
Page 6 of 7. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.CompletedNCT01424462Phase 1
- Fingolimod -Response According to Coping - EvaluationCompletedNCT01420055Phase 4
- Metabolic Effects of a Green Tea Extract in Multiple Sclerosis PatientsCompletedNCT01417312Not applicable
- Impact of Vitamin A on Multiple Sclerosis (MS)Status unknownNCT01417273Phase 4
- Healthy Volunteer Study Using 3 Different Formulations of FirategrastCompletedNCT01416363Phase 1
- Impact of Vitamin A on Gene Expression, in Multiple Sclerosis PatientStatus unknownNCT01407211Phase 4
- Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With ImmunosuppressantCompletedNCT01392872Not applicable
- Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple SclerosisWithdrawnNCT01337427Phase 3
- Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01310166Phase 4
- Advanced MRI Measures of Repair in Alemtuzumab Treated PatientsCompletedNCT01307332Phase 3
- Melatonin in Relapsing-Remitting Multiple Sclerosis PatientsCompletedNCT01279876Phase 2
- Vitamin D Pilot Study in Patients With Multiple SclerosisCompletedNCT01257958Phase 1
- Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With NatalizumabStatus unknownNCT01250678
- Safety Study of BIIB033 in Subjects With Multiple SclerosisCompletedNCT01244139Phase 1
- Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsCompletedNCT01235455
- Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple SclerosisCompletedNCT01158183
- Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)CompletedNCT01143441Phase 1
- A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple SclerosisCompletedNCT01142583
- An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With MitoxantroneCompletedNCT01142518
- A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)CompletedNCT01142492
- An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsCompletedNCT01142453
- An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyCompletedNCT01141751
- A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) SubjectsCompletedNCT01125475
- An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These ParametersCompletedNCT01112345
- Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bCompletedNCT01111656Phase 2
- An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)CompletedNCT01110993
- An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.CompletedNCT01108887
- A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT01081782Phase 2
- Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)CompletedNCT01080053
- To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis PatientsCompletedNCT01080040
- Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)CompletedNCT01080027
- A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in ArgentinaCompletedNCT01080001
- Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®CompletedNCT01075880
- QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in KoreaWithdrawnNCT01071694
- Sensori-motor Integration Training in Multiple SclerosisCompletedNCT01040117Early Phase 1
- Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)TerminatedNCT01039103Phase 2
- A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)TerminatedNCT01037907Phase 2
- The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis PatientsTerminatedNCT01005095Phase 4
- Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)WithdrawnNCT00986960Phase 2
- Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) RelapsesStatus unknownNCT00984984Phase 3
- Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1bCompletedNCT00942591Phase 2
- High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple SclerosisWithdrawnNCT00939549Phase 2
- Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) StudyCompletedNCT00937677
- Exploratory Study on the Timing of Multiple Sclerosis (MS) SymptomsTerminatedNCT00919217
- The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple SclerosisStatus unknownNCT00917839Phase 2
- Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)Status unknownNCT00914758
- Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)Status unknownNCT00910598Phase 4
- Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)CompletedNCT00902135
- Bayer/Cognitive Assessments With Multiple Sclerosis SubjectsCompletedNCT00888277
- Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSCompletedNCT00884481
- A Study for Patients With Relapsing Remitting Multiple SclerosisCompletedNCT00869986Phase 2/3
- Differential Immune Effects of NatalizumabCompletedNCT00859482
- A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MSCompletedNCT00837785Phase 1
- A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder FunctionCompletedNCT00818038
- Autologous Mesenchymal Stem Cell (MSC) Transplantation in MSCompletedNCT00813969Phase 1
- Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon TreatmentCompletedNCT00787657
- A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
- COMPliance With Avonex® PS in Patients With Relapsing-Remitting MSCompletedNCT00675883
- Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to PlaceboCompletedNCT00668343Phase 3
- Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple SclerosisCompletedNCT00645749Phase 1
- Flupirtine as Oral Treatment in Multiple SclerosisTerminatedNCT00623415Phase 2
- Atorvastatin in Relapsing-Remitting Multiple SclerosisCompletedNCT00616187Phase 2
- Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)CompletedNCT00594087Not applicable
- Dose-Escalation Study of T Cell Vaccine in Multiple SclerosisCompletedNCT00587691Phase 1/2
- How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full DoseTerminatedNCT00574041Phase 4
- Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
- Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?CompletedNCT00534261Phase 4
- Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)CompletedNCT00525668Phase 1/2
- Tysabri Observational ProgramCompletedNCT00493298
- Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaCompletedNCT00493116Phase 4
- Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT00492765Phase 4
- GER-009-06-AVX Early Therapy in Multiple SclerosisCompletedNCT00492570
- Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesCompletedNCT00492466Phase 4
- Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With BetaseronCompletedNCT00461396
- Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple SclerosisWithdrawnNCT00429442Phase 3
- Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple SclerosisStatus unknownNCT00411723Phase 1
- An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple SclerosisTerminatedNCT00398528
- Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)CompletedNCT00395317Phase 2
- fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to ControlsCompletedNCT00391352
- BHT-3009 Immunotherapy in Relapsing Remitting Multiple SclerosisCompletedNCT00382629Phase 2
- Omega-3 Fatty Acid Treatment in Multiple SclerosisCompletedNCT00360906Phase 2/3
- A Study to Evaluate the Effectiveness, Tolerability and Safety of LaquinimodCompletedNCT00349193Phase 2
- A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory DifficultiesCompletedNCT00315367Phase 4
- A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)CompletedNCT00292266Phase 3
- Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis SubjectsCompletedNCT00292253Phase 3
- Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisCompletedNCT00276341Phase 3
- Autologous T Cell Vaccine (TCV) for Multiple SclerosisCompletedNCT00245622Phase 2
- A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple SclerosisStatus unknownNCT00242268Phase 3
- Pilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityCompletedNCT00242177Phase 1
- A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)TerminatedNCT00239655Phase 2
- Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MSCompletedNCT00232193
- Study Evaluating CCI-779 in Relapsing Multiple SclerosisCompletedNCT00228397Phase 2
- Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) PatientsStatus unknownNCT00220493Phase 1
- Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple SclerosisTerminatedNCT00219908Phase 2
- A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple SclerosisStatus unknownNCT00217295Phase 2
- Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MSStatus unknownNCT00210301Not applicable
- An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSCompletedNCT00206648Phase 4
- Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00206635
- A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple SclerosisCompletedNCT00203086
- A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.CompletedNCT00203073Phase 2